Enigma Diagnostics and GlaxoSmithKline said today that they have signed a supply and commercialization agreement for molecular diagnostic tests for use on Engima's fully automated, sample-to-answer real-time PCR system, breathing new life into a partnership begun in 2009.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Enigma Diagnostics said today that it has inked a supply and commercialization agreement with GlaxoSmithKline covering its PCR technologies in Europe, India, Brazil, and Russia.
In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.
Efforts spearheaded by Sage Bionetworks and Genetic Alliance hope to encourage drug developers to share precompetitive genomic data from the comparator arms of drug trials and to give study participants more control over their own data generated in clinical investigations.